{"groups":[{"description":"Single oral dose of bosutinib 400 milligram (mg) on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in chronic phase second-line (CP2L) chronic myelogenous leukemia (CML) Part 2 of the study.","id":"FG000","title":"Bosutinib 400 mg (Part 1)"},{"description":"Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study.","id":"FG001","title":"Bosutinib 500 mg (Part 1)"},{"description":"Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in advanced phase (AP) CML Part 2 of the study.","id":"FG002","title":"Bosutinib 600 mg (Part 1)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"FG003","title":"Bosutinib 500 mg, CP2L-CML IM-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"FG004","title":"Bosutinib 500 mg, CP2L-CML IM-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I, D and NI R/I or IM R/I and NI-I CML.","id":"FG005","title":"Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-R CML.","id":"FG006","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-I CML.","id":"FG007","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and NI-R CML.","id":"FG008","title":"Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)"},{"description":"All participants who received bosutinib 500 mg orally once daily in AP CML who were IM R/I or multiple tyrosine kinase inhibitor (Multi-TKI): IM, D and/or NI R/I.","id":"FG009","title":"AP-CML Total (Part 2)"},{"description":"All participants who received bosutinib 500 mg orally once daily in blast phase (BP) CML who were IM R/I or Multi-TKI: IM, D and/or NI R/I.","id":"FG010","title":"BP-CML Total (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with Ph+ ALL","id":"FG011","title":"Bosutinib 500 mg, Ph+ ALL (Part 2)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}],"type":"Continued in to Part 2"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Period 1: Part 1 (Dose Escalation)"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}],"type":"Discontinuation of study by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"4"},{"groupId":"FG010","numSubjects":"4"},{"groupId":"FG011","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"15"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"4"},{"groupId":"FG009","numSubjects":"4"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"37"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"30"},{"groupId":"FG010","numSubjects":"44"},{"groupId":"FG011","numSubjects":"22"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"61"},{"groupId":"FG004","numSubjects":"27"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"9"},{"groupId":"FG008","numSubjects":"5"},{"groupId":"FG009","numSubjects":"9"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"1"}],"type":"Extension study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"comment":"17 participants from Part 1 (Bosutinib 400mg, 500mg, 600mg cohort) continued in Part 2 of the study.","groupId":"FG003","numSubjects":"195"},{"groupId":"FG004","numSubjects":"89"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"38"},{"groupId":"FG007","numSubjects":"50"},{"groupId":"FG008","numSubjects":"26"},{"comment":"1 participant from Part 1 (Bosutinib 600mg cohort) continued in Part 2 of the study.","groupId":"FG009","numSubjects":"79"},{"groupId":"FG010","numSubjects":"64"},{"groupId":"FG011","numSubjects":"24"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"60"},{"groupId":"FG004","numSubjects":"39"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"16"},{"groupId":"FG007","numSubjects":"21"},{"groupId":"FG008","numSubjects":"12"},{"groupId":"FG009","numSubjects":"30"},{"groupId":"FG010","numSubjects":"15"},{"groupId":"FG011","numSubjects":"1"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"135"},{"groupId":"FG004","numSubjects":"50"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"22"},{"groupId":"FG007","numSubjects":"29"},{"groupId":"FG008","numSubjects":"14"},{"groupId":"FG009","numSubjects":"49"},{"groupId":"FG010","numSubjects":"49"},{"groupId":"FG011","numSubjects":"23"}],"type":"NOT COMPLETED"}],"title":"Period 2: Part 2 (Efficacy)"}]}